Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
Hiroki Kawabata,1 Minoru Satoh,2 Kazuhiro Yatera1 1Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, 807-8555, Japan; 2Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, 807-8555, Japan...
Guardado en:
Autores principales: | Kawabata H, Satoh M, Yatera K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/71c31f0fde8d4774bda86c2ad39f287c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati M, et al.
Publicado: (2019) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar P
Publicado: (2017) -
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: John Davison, et al.
Publicado: (2021) -
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Angelantonio Maglio, et al.
Publicado: (2021) -
Rheumatoid arthritis hand lesions assessed with outcome measures in rheumatoid arthritis clinical trials-rheumatoid arthritis magnetic resonance imaging score – proposing an extended rheumatoid arthritis magnetic resonance imaging score
por: M. del Carmen Larios-Forte, et al.
Publicado: (2021)